Epirium Bio

Epirium is a clinical stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue regeneration, potentially resulting in novel and clinically significant therapeutic approaches to currently intractable neuromuscular and neurodegenerative diseases, including primary and secondary cardiomyopathies. The Company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium intends to advance its first clinical candidate (EB 002) this year, initially in Becker muscular dystrophy, followed by drug development targeting other progressive neuromuscular and neurodegenerative disorders associated with mitochondrial depletion.

Go to website: https://epirium.com/